DOP2010000222A - 3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa - Google Patents

3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa

Info

Publication number
DOP2010000222A
DOP2010000222A DO2010000222A DO2010000222A DOP2010000222A DO P2010000222 A DOP2010000222 A DO P2010000222A DO 2010000222 A DO2010000222 A DO 2010000222A DO 2010000222 A DO2010000222 A DO 2010000222A DO P2010000222 A DOP2010000222 A DO P2010000222A
Authority
DO
Dominican Republic
Prior art keywords
phenoxi
benzamida
pirrolidin
dimethylphenyl
fluoro
Prior art date
Application number
DO2010000222A
Other languages
English (en)
Spanish (es)
Inventor
Nuria Diaz Buezo
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2010000222A publication Critical patent/DOP2010000222A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DO2010000222A 2008-01-22 2010-07-20 3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa DOP2010000222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25

Publications (1)

Publication Number Publication Date
DOP2010000222A true DOP2010000222A (es) 2015-11-15

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000222A DOP2010000222A (es) 2008-01-22 2010-07-20 3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa

Country Status (32)

Country Link
US (2) US7709522B2 (https=)
EP (1) EP2252581B1 (https=)
JP (1) JP5345637B2 (https=)
KR (1) KR101172170B1 (https=)
CN (1) CN101925576B (https=)
AR (1) AR070158A1 (https=)
AU (1) AU2009206653B2 (https=)
BR (1) BRPI0907382B8 (https=)
CA (1) CA2713025C (https=)
CO (1) CO6290644A2 (https=)
CY (1) CY1113071T1 (https=)
DK (1) DK2252581T3 (https=)
DO (1) DOP2010000222A (https=)
EA (1) EA017484B1 (https=)
EC (1) ECSP10010365A (https=)
ES (1) ES2388708T3 (https=)
HR (1) HRP20120558T1 (https=)
IL (1) IL206038A (https=)
JO (1) JO2797B1 (https=)
MA (1) MA32751B1 (https=)
MX (1) MX2010007849A (https=)
MY (1) MY163014A (https=)
NZ (1) NZ586225A (https=)
PE (1) PE20091317A1 (https=)
PL (1) PL2252581T3 (https=)
PT (1) PT2252581E (https=)
SI (1) SI2252581T1 (https=)
TN (1) TN2010000306A1 (https=)
TW (1) TWI422369B (https=)
UA (1) UA100715C2 (https=)
WO (1) WO2009094260A1 (https=)
ZA (1) ZA201003908B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091439A1 (es) * 2008-01-22 2009-10-19 Takeda Pharmaceutical Compuestos triciclicos como antagonistas de crf
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
EP2757881A4 (en) 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
EP2773352B1 (en) 2011-12-09 2017-06-28 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
CA2911231C (en) * 2013-05-24 2021-12-07 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
ES2926533T3 (es) 2017-03-17 2022-10-26 Scripps Research Inst Antagonistas del receptor opioideo kappa y productos y métodos relacionados con los mismos
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2022268720A1 (en) 2021-05-04 2023-12-21 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
JP2025503646A (ja) * 2022-01-10 2025-02-04 ヤンセン ファーマシューティカルズ,インコーポレーテッド うつ病の治療のための組成物及び方法
EP4463143A1 (en) * 2022-01-10 2024-11-20 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170547A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) * 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
WO2000069858A1 (en) * 1999-05-12 2000-11-23 F. Hoffmann-La Roche Ag Imidazodiazepine derivative
JP2004510789A (ja) * 2000-10-05 2004-04-08 モーラー,ハンス 選択的抗不安治療薬
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) * 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
CN1756746A (zh) * 2003-03-07 2006-04-05 伊莱利利公司 作为阿片样物质受体拮抗剂的6-取代的烟酰胺衍生物
US7396943B2 (en) * 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
AU2005222640A1 (en) * 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
EP1727788B1 (en) * 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1730140B1 (en) * 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
JP2007529523A (ja) * 2004-03-15 2007-10-25 イーライ リリー アンド カンパニー 肥満症を治療するためのオピオイド受容体拮抗物質としての4−(5−アミノメチル)−インドール−1−イルメチル)−ベンズアミド誘導体および関連化合物
CA2557794A1 (en) * 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
DK2001456T3 (da) 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
WO2008021849A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
CN101511808A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
PE20091317A1 (es) 2009-09-03
DK2252581T3 (da) 2012-07-16
US20100197669A1 (en) 2010-08-05
JP2011524850A (ja) 2011-09-08
CA2713025C (en) 2012-12-04
BRPI0907382B8 (pt) 2021-05-25
CN101925576B (zh) 2013-02-06
ECSP10010365A (es) 2010-08-31
PL2252581T3 (pl) 2012-10-31
KR101172170B1 (ko) 2012-08-07
AU2009206653B2 (en) 2013-07-18
EA017484B1 (ru) 2012-12-28
BRPI0907382B1 (pt) 2020-03-10
US8173695B2 (en) 2012-05-08
UA100715C2 (ru) 2013-01-25
HK1146822A1 (en) 2011-07-15
WO2009094260A1 (en) 2009-07-30
SI2252581T1 (sl) 2012-09-28
MA32751B1 (fr) 2011-11-01
NZ586225A (en) 2012-05-25
MY163014A (en) 2017-07-31
BRPI0907382A2 (pt) 2015-07-21
AR070158A1 (es) 2010-03-17
TN2010000306A1 (en) 2011-11-11
US20090186873A1 (en) 2009-07-23
KR20100095639A (ko) 2010-08-31
MX2010007849A (es) 2010-08-09
ZA201003908B (en) 2011-11-30
ES2388708T3 (es) 2012-10-17
JO2797B1 (en) 2014-03-15
CA2713025A1 (en) 2009-07-30
EP2252581B1 (en) 2012-06-20
JP5345637B2 (ja) 2013-11-20
PT2252581E (pt) 2012-08-31
EA201070877A1 (ru) 2010-12-30
CO6290644A2 (es) 2011-06-20
TW200936129A (en) 2009-09-01
IL206038A0 (en) 2010-11-30
HRP20120558T1 (hr) 2012-10-31
AU2009206653A1 (en) 2009-07-30
EP2252581A1 (en) 2010-11-24
CY1113071T1 (el) 2016-04-13
IL206038A (en) 2013-11-28
TWI422369B (zh) 2014-01-11
US7709522B2 (en) 2010-05-04
CN101925576A (zh) 2010-12-22

Similar Documents

Publication Publication Date Title
DOP2010000222A (es) 3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa
AR079198A1 (es) Sales de 4-(2-((5-metil-1-(2-naftalenil) -1h pirazol -3- il)oxi) etil) morfolina
TNSN08089A1 (en) Substituted benzimidazoles and methods of preparation
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
CO6210732A2 (es) Indazoles sustituidos con amina como inhibidores de poli(adp-ribosa) polimerasa (parp)
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
CL2011002925A1 (es) Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1.
CO6592093A2 (es) Polimorfos y solvatos de clorhidrato de 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi9etil)morfolina
ES2723277T3 (es) Una forma sólida de clorhidrato de (S)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
DOP2007000068A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
MX2010001837A (es) Derivados de 4-pirimidinasulfamida.
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
CR20110369A (es) Derivados de quinazolinona útiles como antagonistas de vanilloides
HRP20182059T1 (hr) Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja
CO6300951A2 (es) Derivados de azaciclilisoquinolinona e- isoindolinona como antagonistas de la histamina-3
LT3456340T (lt) Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
CL2017000069A1 (es) Derivado de hidantoina.
DOP2011000398A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
CR11559A (es) Antagonista del receptor opioide selectivo kappa
CO6531487A2 (es) Proceso para la elaboración de compuestos orgánicos
EA201390966A1 (ru) Замещенные соединения [(5h-пирроло[2,1-c][1,4]бензодиазепин-11-ил)пиперазин-1-ил]-2,2-диметилпропановой кислоты в качестве обратных агонистов h1/антагонистов 5-htдвойного действия
MX2011011177A (es) Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina.
EP2409966A4 (en) AMINOCYCLITOL COMPOUNDS, METHOD FOR THEIR OBTAINMENT AND USES THEREOF
HN2010001319A (es) Antagonista del receptor opioide selectivo kappa
BRPI0906982A2 (pt) N-[3-bromo-2-cloro-4-(4,5-di-hidro-ih-imidazol-2-ilmetil )-fenil]-metanossulfonamida como agonista parcial adrenégico alfa-1 a para o tratamento de incontinência